Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches.
CONCLUSION: NSCLC patients with brain metastases harboring EGFR or ALK mutations have superior OS compared to wild-type patients. No PFS or OS benefit was found with the addition of TKIs to RT.
PMID: 31812932 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Singh R, Lehrer EJ, Ko S, Peterson J, Lou Y, Porter AB, Kotecha R, Brown PD, Zaorsky NG, Trifiletti DM Tags: Radiother Oncol Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Radiation Therapy | Radiology | Science | Study